Bruce Booth
CIK: 0001451612
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (227 total)
- Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.5K shares at avg. $108.28$162K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect2.7K shares at avg. $107.76$291K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect14.8K shares at avg. $106.63$1.6M - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect5.5K shares at avg. $105.78$587K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect7.7K shares at avg. $110.67$855K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect2.1K shares at avg. $106.63$227K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect19.4K shares at avg. $107.76$2.1M - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect130 shares at avg. $111.20$14K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.1K shares at avg. $110.67$119K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.1K shares at avg. $109.75$121K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect10.8K shares at avg. $108.28$1.2M - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect8K shares at avg. $109.75$874K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect934 shares at avg. $111.20$104K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect770 shares at avg. $105.78$81K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.2K shares at avg. $110.67$133K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect907 shares at avg. $111.20$101K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect157 shares at avg. $111.20$17K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect10.7K shares at avg. $108.28$1.2M - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect7.8K shares at avg. $109.75$860K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect7.6K shares at avg. $110.67$841K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.7K shares at avg. $108.28$183K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect1.2K shares at avg. $109.75$136K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect2.3K shares at avg. $106.63$247K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect848 shares at avg. $105.78$90K - Jun 29, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Indirect3K shares at avg. $107.76$326K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 29, 2026 |  KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,498 | $108.28 | $162,203 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,698 | $107.76 | $290,736 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 14,798 | $106.63 | $1,577,911 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 5,549 | $105.78 | $586,973 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 7,723 | $110.67 | $854,704 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,133 | $106.63 | $227,442 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 19,419 | $107.76 | $2,092,591 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 130 | $111.20 | $14,456 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,078 | $110.67 | $119,302 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,104 | $109.75 | $121,164 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 10,848 | $108.28 | $1,174,621 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 7,968 | $109.75 | $874,488 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 934 | $111.20 | $103,861 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 770 | $105.78 | $81,451 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,199 | $110.67 | $132,693 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 907 | $111.20 | $100,858 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 157 | $111.20 | $17,458 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 10,658 | $108.28 | $1,154,048 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 7,833 | $109.75 | $859,672 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 7,602 | $110.67 | $841,313 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,688 | $108.28 | $182,777 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,239 | $109.75 | $135,980 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,318 | $106.63 | $247,168 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 848 | $105.78 | $89,701 | Indirect |
| Jun 29, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 3,024 | $107.76 | $325,866 | Indirect |
1-25 of 227 transactions
About Booth Bruce
Booth Bruce (SEC CIK 0001451612) files insider reports with the SEC as Director of Kymera Therapeutics, Inc. (KYMR), Director of Sionna Therapeutics, Inc. (SION) and Director of Vigil Neuroscience, Inc. (VIGL).
Signal8 holds 25 ownership filings by Booth Bruce (1 Form 3, 24 Form 4), filed between Feb 6, 2025 and Jul 2, 2026. Those filings report 227 transactions, from Feb 10, 2025 to Jun 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Booth Bruce's filings is in WATERTOWN, MA.
Recent filings by Booth Bruce
- Jun 29, 2026: Open-market sales of KYMR shares (25 lines, Form 4, code S).
Other insiders filing for Kymera Therapeutics, Inc. (KYMR)
- Mainolfi Nello, Chief Executive Officer
- Adams Brian, Chief Legal Officer
- Rooney Terence, Chief Medical Officer
- Jacobs Bruce N., Chief Financial Officer
- Goodman Noah, Chief Business Officer
- BVF PARTNERS L P/IL, Director